Lexaria Bioscience (LEXX) Change in Receivables (2010 - 2026)
Lexaria Bioscience (LEXX) posted Change in Receivables of $6969.0 for Q2 2026, up 115.15% sequentially from -$46015.0 in Q1 2026, and down 74.15% YoY from $26964.0 in Q2 2025.
Lexaria Bioscience (LEXX) Change in Receivables (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Change in Receivables for 17 years, with the latest figure at $6969.0 in Q2 2026.
- Quarterly Change in Receivables fell 74.15% year-over-year to $6969.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$309131.0 (down 296.34% YoY) and the FY2025 annual result came in at $213881.0, up 501.62% from the prior year.
- Change in Receivables rose to $6969.0 in Q2 2026 per LEXX's latest filing, from -$46015.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $408045.0 in Q4 2023 and troughed at -$280314.0 in Q4 2025.
- A 5-year average of -$19614.9 and a median of -$8294.5 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables surged 382.68% in 2023, then slumped 1660.55% in 2024.
- Over 5 years, Change in Receivables stood at $84538.0 in 2022, then soared by 382.68% to $408045.0 in 2023, then plunged by 73.28% to $109014.0 in 2024, then sank by 357.14% to -$280314.0 in 2025, then surged by 102.49% to $6969.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $6969.0, -$46015.0, and -$280314.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 6,969.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 6,969.00 |
| May 31, 2026 | 6,969.00 |
| Feb 28, 2026 | -46,015.00 |
| Feb 28, 2026 | -46,015.00 |
| Nov 30, 2025 | -280,314.00 |
| Nov 30, 2025 | -280,314.00 |
| Aug 31, 2025 | 10,229.00 |
| Aug 31, 2025 | 10,229.00 |
| May 31, 2025 | 26,964.00 |
| May 31, 2025 | 26,964.00 |
| Feb 28, 2025 | 67,674.00 |
| Feb 28, 2025 | 67,674.00 |
| Nov 30, 2024 | 109,014.00 |
| Nov 30, 2024 | 109,014.00 |
| Aug 31, 2024 | -46,208.00 |
| Aug 31, 2024 | -46,208.00 |
| May 31, 2024 | -148,645.00 |
| May 31, 2024 | -148,645.00 |
| Feb 29, 2024 | -177,641.00 |
| Feb 29, 2024 | -177,641.00 |